Investor Relations (IR) Questions: Arrowhead Research Corp ARWR
Click here to return to the biotech IRQ Index
Answers received: October 2012
The following was information I gathered from the company's website + a few telephone conversations with Vince Anzalone at the compnay. Once I put it all together I emailed it to Vince for confirmation that the information was correct.
When is the last time Arrow Head raised cash through an offering (diluted)? August 2012, raised $6.2 million
How much cash (not cash equivalents) does Arrow Head have? 3.3 million as of June 30 + 6.2 mil from offering.
What and approximately when is the next known catalyst?
ARC-520 for Hepatitis B
They are working on an IND. They are looking at around mid 2013 before they advance to testing on humans.
Adipotide Weight loss drug
Currently in a Phase 1 trial. No published results expected until around mid-2013. This drug candidate is also being explored as an oncology drug and is in a pre-clinical stage.
CALAA-01
Currently in phase 1b. This is an open-label, dose-escalating study of the safety of intravenous CALAA-01 in adults with solid tumors refractory to stand-of-care therapies. The company has not provided guidance on a time frame when result/info will be made available.
CRLX-101
Currently at phase 2. This oncology product is partnered with Cerulean Pharma and they are picking up expenses related to the ongoing trials. They have some results but have not released them yet and have not said when they will do so. However, they have moved forward with the trials and have actually expanded them.
Tubulin Inhibitor
Oncology candidate currently in pre-clinical stage. Partnered with Tube Pharma who is picking up the expenses.
What is Arrow Head's quarterly cash burn? $1.1 to $1.5 million per month.
Credit with Lincoln Park Capital which was put in place to provide financing of up to $15 million that may be drawn down over three years, as needed. So far they've utilitzed $1 million of the credit line.
The following was information I gathered from the company's website + a few telephone conversations with Vince Anzalone at the compnay. Once I put it all together I emailed it to Vince for confirmation that the information was correct.
When is the last time Arrow Head raised cash through an offering (diluted)? August 2012, raised $6.2 million
How much cash (not cash equivalents) does Arrow Head have? 3.3 million as of June 30 + 6.2 mil from offering.
What and approximately when is the next known catalyst?
ARC-520 for Hepatitis B
They are working on an IND. They are looking at around mid 2013 before they advance to testing on humans.
Adipotide Weight loss drug
Currently in a Phase 1 trial. No published results expected until around mid-2013. This drug candidate is also being explored as an oncology drug and is in a pre-clinical stage.
CALAA-01
Currently in phase 1b. This is an open-label, dose-escalating study of the safety of intravenous CALAA-01 in adults with solid tumors refractory to stand-of-care therapies. The company has not provided guidance on a time frame when result/info will be made available.
CRLX-101
Currently at phase 2. This oncology product is partnered with Cerulean Pharma and they are picking up expenses related to the ongoing trials. They have some results but have not released them yet and have not said when they will do so. However, they have moved forward with the trials and have actually expanded them.
Tubulin Inhibitor
Oncology candidate currently in pre-clinical stage. Partnered with Tube Pharma who is picking up the expenses.
What is Arrow Head's quarterly cash burn? $1.1 to $1.5 million per month.
- Does Arrow Head have an existing line of credit and if so how much can they draw against it?
Credit with Lincoln Park Capital which was put in place to provide financing of up to $15 million that may be drawn down over three years, as needed. So far they've utilitzed $1 million of the credit line.